Top

Gepubliceerd in:

2014 | OriginalPaper | Hoofdstuk

5. Nierinsufficiëntie en medicatie

Auteurs : Drs. Anne Esselink, Dr. Nynke (D.) Scherpbier-de Haan, Dr. Kees Kramers

Gepubliceerd in: Inzichten in de nefrologie

Uitgeverij: Bohn Stafleu van Loghum

Samenvatting

In de huisartsenpraktijk neemt het aantal patiënten met een verminderde nierfunctie toe. Veel geneesmiddelen worden renaal uitgescheiden, wat onder andere consequenties heeft voor de dosering van deze geneesmiddelen. Het is in de dagelijkse praktijk niet altijd gemakkelijk hiermee om te gaan. In dit hoofdstuk gaan we dieper in op de beoordeling van de nierfunctie en geven we vervolgens achtergrondinformatie en praktische adviezen omtrent het gebruik van antibiotica, orale antidiabetica, ACE-remmers, NSAID’s, diuretica en de nieuwe directe orale anticoagulantia (DOAC) bij nierinsufficiëntie.

vorige hoofdstuk Acute nierinsufficiëntie

volgende hoofdstuk Chronische nierschade

Harm-rapport (Hospital Admissions Related to Medication). Utrecht: Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology & Pharmacotherapy, November 2006.

Leendertse AJ, Dijk EA van, Smet PA de, Egberts TC, Bemt PM van den. Contribution of renal impairment to potentially preventable medication-related hospital admissions. Ann Pharmacother. 2012 May;46(5):625–33.PubMedCrossRef

Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockroft-Gault equations for estimating renal function. J Am Soc Nephrol. 2005;16:763–73.PubMedCrossRef

Verhave JC, Kramers C, Wetzels JFM. Nieuwe formule leidt tot betere schattingen. Pharm Weekbl. 2007;142(40):18–21.

Felts JH, Hayes DM, Gergen JA, Toole JF. Neural, hematologic and bacteriologic effects of nitrofurantoin in renal insufficiency. Am J Med. 1971;51:331–9.PubMedCrossRef

Thieler H, Meyer W. Nil nocere! Severe polyneuropathy during nitrofurantoin therapy of renal insufficiency. Dtsch Gesundheitsw. 1968;23:488–91.PubMed

Geerts AF, et al. Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care. Eur J Clin Pharmacol. 2013 Sep;69(9):1701–7.PubMedCrossRef

Siber GR, Gorham CC, Ericson JF, Smith AL. Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. Rev Infect Dis. 1982 Mar-Apr;4(2):566–78.PubMedCrossRef

Rigalleau V, et al. Estimation of renal function in patients with diabetes. Diabetes Metab. 2011;37(5):359–66.PubMedCrossRef

10.

Linden CMJ van der, Knol W, Marum RJ van, Jansen PA. Lactaatacidose bij een 85-jarige vrouw door behandeling met metformine. Ned Tijdschr Geneeskd. 2007;151:977–80.PubMed

11.

Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf. 1999:489–503.

12.

Graham GG, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50 (2):81-98.PubMedCrossRef

13.

Jönsson A, Rydberg T, Sterner G, Melander A. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol. 1998;53:429–35.PubMedCrossRef

14.

Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996;39:1617–24.PubMedCrossRef

15.

Marbury TC, et al. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther. 2000 Jan;67(1):7–15.PubMedCrossRef

16.

Lam FYW, Banerji S, Hatfield C, Talbert RL. Principles of drug administration in renal insufficiency. Clin Pharmocokinet. 1997 Jan;32 (1):30–57.

17.

Boulton D, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet. 2011 Apr;50(4):253–65.PubMedCrossRef

18.

Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab. 2011;13:947–54.PubMedCrossRef

19.

Bergman AJ, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007;30:1862–4.PubMedCrossRef

20.

Linneberg H, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 2007;64:317–27.CrossRef

21.

Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009 Dec;68(6):898–905.PubMedCentralPubMedCrossRef

22.

Bootsma JE, et al. Adherence to biochemical monitoring recommendations in patients starting with renin angiotensin system inhibitors: a retrospective cohort study in the Netherlands. Drug Saf. 2011 Jul 1;34(7):605–14.PubMedCrossRef

23.

Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999 May 31;106(5B):13S–24S.

24.

Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. New Engl J Med. 1984;310:563–72.PubMedCrossRef

25.

Niemeyer C, Hasenfuss G, Wais U, Knauf H, Schäfer-Korting M, Mutschler E. Pharmacokinetics of hydrochloorthiazide in relation to renal function. Eur J Clin Pharmacol. 1983;24:661–5.PubMedCrossRef

26.

Traeger A, et al. Pharmacokinetic and pharmacodynamic effects of furosemide in patients with impaired renal function. Int J Clin Pharmacol Ther Toxicol. 1984;22(9):481–6.PubMed

27.

Syropoulus AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012;120(15):2954–62.CrossRef

28.

Steffel J, Hindrick G. Apixaban in renal insufficiency: successful navigation between the Scylla and Charybdis. Eur Heart J. 2012;33:2766–8.PubMedCrossRef

Titel: Nierinsufficiëntie en medicatie
Auteurs: Drs. Anne Esselink
Dr. Nynke (D.) Scherpbier-de Haan
Dr. Kees Kramers
Uitgeverij: Bohn Stafleu van Loghum
Boek: Inzichten in de nefrologie
Print ISBN: 978-90-368-0837-8

Elektronisch ISBN: 978-90-368-0838-5

Copyright: 2014
DOI: https://doi.org/10.1007/978-90-368-0838-5_5

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen